{"word_count": 308, "character_count": 2437}
Auteur : Sarah Zheng, journaliste de&#160;South China Morning Post&#160;à Hong KongProduction :&#160;South China Morning Post, quotidien de langue anglaise publié à Hong Kong depuis 1903. Sa diffusion s’élève à 104 000 exemplaires. Il est publié par le groupe SCMP, propriété de du groupe Alibaba depuis 2015.Diffusion : site du journal&#160;South China Morning PostDate et Heure : 21 juillet 2020, 13:32https://www.youtube.com/watch?v=wQ-aIHTvuvk&#38;feature=emb_logoCoronavirus: Inside a Chinese lab joining global race to find a vaccine, South China Moring Post, 22/06/2020- Phase-two trial by team of Chinese scientists ‘induces significant neutralising antibody responses’, paper in peer-reviewed The Lancet reports- Study out of Britain’s Jenner Institute finds antibodies are still high up to two months after vaccine administeredSource : Sarah Zheng, "In coronavirus vaccine race, Chinese and Oxford trials produce immune responses, offering hope in pandemic", South China Morning Post, 21/07/2020. URL : https://www.scmp.com/news/china/science/article/3094034/coronavirus-vaccine-race-chinese-and-/xford-trials-produce (consulté le 21/07/2020).Voir également :"Chine : un essai en phase 2 conclut qu'un candidat vaccin est sûr et induit une réponse immunitaire (The Lancet)", Xinhua News, 22/07/2020. URL : http://french.xinhuanet.com/2020-07/22/c_139232059.htm (consulté le 22/07/2020).Article de référence :Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li [et al.], "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial", The Lancet, 20/07/2020. DOI : https://doi.org/10.1016/S0140-6736(20)31605-6 (consulté le 21/07/2020).Naor Bar-Zeev, William J Moss, "Encouraging results from phase 1/2 COVID-19 vaccine trials", The Lancet, 20/07/2020. DOI : https://doi.org/10.1016/S0140-6736(20)31611-1 (consulté le 21/07/2020).Pedro M Folegatti, Katie J Ewer, Parvinder K Aley [et al.], "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial", The Lancet, 20/07/2020. DOI : https://doi.org/10.1016/S0140-6736(20)31604-4 (consulté le 21/07/2020).Photo "à la une" : Two vaccine trials – one by a Chinese team and the other out of Oxford in Britain – have produced an immune response in trial patients. © Xinhua